Sherman Rachel E.
Known title: DirectorCIK: 0001784705
Associated companies
Transaction History
| WGS | ▲ Buy | Option Exercise | 45,454 | $0 | 5/2/2023 | View on chart |
| WGS | ▲ Buy | Option Exercise | 12,836 | — | 4/27/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 45,454 | $0 | 5/2/2023 | View on chart |
| WGS | ▲ Buy | Option Exercise | 12,836 | — | 4/27/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
GeneDx Shares New Genomic Newborn Screening Data
GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.
GeneDx Shares New Genomic Newborn Screening Data. GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.